Pancreas Transplantation — MCQs
In orthotopic liver transplantation, which is the best way to achieve bile drainage in the donor liver
What is the most common immunosuppressant regimen used in renal transplant for maintenance?
Wrong statement about SGLT (sodium-glucose linked transporter):
Which is the common site of injection of islet cells in islet cell transplant for diabetes mellitus?
Which of the following is NOT a common complication of acute pancreatitis?
Which of the following is not a recognized complication of chronic pancreatitis?
All are indications of liver transplantation except:
What is the method of delivery for islet cell transplantation in diabetes mellitus?
Which of the following is a cause of post-transplantation hypertension? I. Rejection II. Cyclosporine nephrotoxicity III. Renal transplant artery stenosis (RTAS) IV. Recurrent disease in the allograft. Select the correct option.
Xenograft is transplantation of tissue:
Pancreas Transplantation Indian Medical PG Practice Questions and MCQs
Question 1: In orthotopic liver transplantation, which is the best way to achieve bile drainage in the donor liver
- A. Donor bile duct with recipient bile duct or Roux-en-Y choledochojejunostomy (Correct Answer)
- B. Donor bile duct with jejunum of recipient
- C. Donor bile duct with duodenum of recipient
- D. External drainage for a few days followed by choledochojejunostomy
Explanation: ***Donor bile duct with recipient bile duct or Roux en Y choledochojejunostomy*** - The most common and preferred method for bile drainage in **orthotopic liver transplantation** is a **duct-to-duct anastomosis** between the donor and recipient bile ducts. - If a primary duct-to-duct anastomosis is not feasible due to size mismatch, damage, or other reasons, a **Roux-en-Y choledochojejunostomy** is performed, which involves connecting the donor bile duct to a Roux limb of the jejunum. *External drainage for few days followed by choledochojejunostomy* - **External bile drainage** is generally avoided in liver transplantation due to increased risks of **infection** and complications like **bile leaks**. - It does not provide a definitive long-term solution for bile flow and necessitates a secondary, more complex surgical procedure for permanent drainage. *Donor bile duct with jejunum of recipient* - Connecting the donor bile duct directly to the jejunum (without a Roux-en-Y limb) would expose the biliary tree to **intestinal contents**, increasing the risk of **ascending cholangitis**. - The Roux-en-Y configuration is crucial to prevent reflux of food and bacteria into the biliary system, which is not achieved by a simple choledochojejunostomy. *Donor bile duct with duodenum of recipient* - Anastomosing the donor bile duct directly to the **duodenum** significantly increases the risk of **reflux of duodenal contents**, including digestive enzymes and bacteria, into the biliary system. - This reflux can lead to severe and recurrent **cholangitis**, stricture formation, and potential graft failure due to chronic inflammation and infection.
Question 2: What is the most common immunosuppressant regimen used in renal transplant for maintenance?
- A. Calcineurin inhibitors + Purine antagonists + Basliximab
- B. Glucocorticoids + Cyclophosphamide
- C. Cyclophosphamide + Purine antagonists + Glucocorticoids
- D. Calcineurin inhibitors + Purine antagonists + Glucocorticoids (Correct Answer)
Explanation: ***Calcineurin inhibitors + Purine antagonists + Glucocorticoids*** - This triple therapy regimen is the **most common and effective** approach for long-term maintenance immunosuppression in renal transplant recipients [1]. - **Calcineurin inhibitors** (e.g., tacrolimus, cyclosporine) are the cornerstone for preventing T-cell activation, **purine antagonists** (e.g., mycophenolate mofetil, azathioprine) inhibit lymphocyte proliferation, and **glucocorticoids** provide broad anti-inflammatory effects [1]. *Calcineurin inhibitors + Purine antagonists + Basliximab* - **Basiliximab** is typically used for **induction therapy** (immediately post-transplant) to prevent acute rejection by blocking the IL-2 receptor, not as a long-term maintenance component. - The standard maintenance regimen *replaces* induction agents like basiliximab with a long-term steroid or calcineurin inhibitor alongside a purine antagonist. *Glucocorticoids + Cyclophosphamide* - **Cyclophosphamide** is a potent alkylating agent primarily used in specific autoimmune diseases or certain cancers, and its use in transplant is generally limited to cases of organ rejection resistant to standard therapy due to its significant toxicity. - This combination is **not a standard maintenance regimen** for renal transplant due to the high toxicity and side effects of cyclophosphamide. *Cyclophosphamide + Purine antagonists + Glucocorticoids* - As mentioned, **cyclophosphamide** is not a first-line agent for maintenance immunosuppression in renal transplant due to its severe side effect profile, including myelosuppression and hemorrhagic cystitis. - While purine antagonists and glucocorticoids are components of maintenance therapy, the inclusion of cyclophosphamide makes this an **uncommon and usually unfavorable regimen** for long-term use.
Question 3: Wrong statement about SGLT (sodium-glucose linked transporter):
- A. SGLT2 inhibitors worsen heart failure (Correct Answer)
- B. SGLT2 inhibitors produce weight loss
- C. SGLT1 is present in the intestine and kidneys
- D. SGLT1 has low capacity and high affinity
Explanation: ***SGLT2 inhibitors worsen heart failure*** - This statement is incorrect because **SGLT2 inhibitors** have been shown to **improve outcomes in heart failure**, reducing hospitalizations and cardiovascular mortality, even in patients without diabetes. - Their beneficial effects in heart failure are attributed to mechanisms such as **osmotic diuresis**, natriuresis, improved cardiac energetics, and reduced preload and afterload. - Landmark trials like **DAPA-HF** and **EMPEROR-Reduced** demonstrated significant benefits in heart failure with reduced ejection fraction (HFrEF). *SGLT2 inhibitors produce weight loss* - **SGLT2 inhibitors** cause **glucosuria** (excretion of glucose in the urine), leading to a loss of calories and subsequent modest weight loss (2-3 kg). - This effect is a common and beneficial side effect, contributing to improved metabolic profiles in patients with type 2 diabetes. *SGLT1 is present in the intestine and kidneys* - **SGLT1** is the primary transporter responsible for glucose absorption in the **small intestine** and is also found in the **kidneys' S3 segment** of the proximal tubule. - In the kidneys, it plays a minor role in glucose reabsorption compared to SGLT2, but it is critical for dietary glucose absorption. *SGLT1 has low capacity and high affinity* - **SGLT1** is characterized by its **high affinity** for glucose (Km ~0.4 mM), allowing it to efficiently reabsorb glucose even at low concentrations. - However, it has a **lower capacity** compared to SGLT2, meaning it reabsorbs a smaller absolute amount of glucose despite its strong binding.
Question 4: Which is the common site of injection of islet cells in islet cell transplant for diabetes mellitus?
- A. Portal vein (Correct Answer)
- B. Forearm muscles
- C. Pancreas
- D. Pelvis
Explanation: ***Portal vein*** - Islet cells are infused into the **portal vein** to allow them to be carried to the liver, where they engraft and begin producing insulin. - The liver provides a **vascular-rich environment** suitable for islet cell survival and integration, and the portal system allows direct access to the systemic circulation for insulin delivery. *Forearm muscles* - While muscles can be used for cell delivery in some experimental therapies, they do not provide the **optimal vascularity** or direct circulatory access for effective islet cell function and insulin secretion required for diabetes management. - The forearm muscles would not allow the instilled insulin to be directly sent to target organs via **systemic circulation**. *Pancreas* - Directly injecting islet cells into the pancreas is technically challenging due to its **exocrine function** and has a higher risk of inflammation and damage to the remaining pancreatic tissue. - The goal is to replace the function of the pancreatic islets rather than directly integrate them into the diseased or damaged pancreas, especially since the autoimmune process often targets the pancreas itself. *Pelvis* - The pelvis, while having some vascularity, is not a primary site for islet cell transplantation due to its **lack of direct involvement** in glucose metabolism regulation and less optimal vascular architecture for widespread insulin distribution. - There is no specific physiological advantage for engrafting islet cells in the pelvis over other sites like the liver, and it would not ensure optimal insulin delivery to the systemic circulation.
Question 5: Which of the following is NOT a common complication of acute pancreatitis?
- A. Subcutaneous fat necrosis
- B. Hyperlipidemia
- C. Hypercalcemia (Correct Answer)
- D. Increased amylase level
Explanation: ***Hypercalcemia*** - Acute pancreatitis is primarily associated with **increased amylase levels** and **hyperlipidemia**, while hypercalcemia is generally a separate condition. - It is not a classical complication or result of acute pancreatitis, but rather might be a cause in cases like **hyperparathyroidism** [1]. *Subcutaneous fat necrosis* - This occurs as a result of **lipolysis** during acute pancreatitis due to the release of **lipases** into circulation [1]. - It is characterized by the presence of **fat necrosis** on the abdomen or buttocks. *Increased amylase level* - A hallmark of acute pancreatitis is **elevated levels of amylase** and sometimes lipase, indicating pancreatic inflammation [1]. - The rise typically occurs within the first 24 hours of the onset of pancreatitis. *Hyperlipidemia* - This is often found in acute pancreatitis due to excess **lipolysis**, leading to elevated triglycerides in the blood [1]. - It can be both a cause and a consequence of pancreatic inflammation, contributing to the disease process [1].
Question 6: Which of the following is not a recognized complication of chronic pancreatitis?
- A. Renal artery thrombosis (Correct Answer)
- B. Pancreatic pseudocyst
- C. Splenic vein thrombosis
- D. Pancreatic fistula
Explanation: ***Renal artery thrombosis*** - **Renal artery thrombosis** is generally associated with conditions like **atherosclerosis**, atrial fibrillation, or vasculitis, not directly with chronic pancreatitis. - While chronic pancreatitis can lead to systemic complications, direct renal arterial clotting is an atypical and **uncommon sequela**. *Pancreatic pseudocyst* - **Pancreatic pseudocysts** are common complications of chronic pancreatitis, occurring when fluid collections around the pancreas become walled off by fibrous tissue [1]. - They can cause pain, obstruction, and even rupture if left untreated [2]. *Splenic vein thrombosis* - **Splenic vein thrombosis** can result from inflammation and compression of the splenic vein by the diseased pancreatic tissue in chronic pancreatitis [1]. - This can lead to **splenomegaly** and **gastric varices** due to increased pressure in the portal system. *Pancreatic fistula* - A **pancreatic fistula** occurs when pancreatic fluid leaks from the gland, often forming a connection to another organ or the skin [2]. - This is a well-recognized complication of both acute and chronic pancreatitis, usually due to ductal disruption.
Question 7: All are indications of liver transplantation except:
- A. Primary sclerosing cholangitis
- B. Fulminant hepatitis
- C. Alcoholic cirrhosis
- D. Primary biliary cirrhosis
- E. Hepatic adenomas (Correct Answer)
Explanation: ***Hepatic adenomas*** - **Hepatic adenomas** are benign liver tumors that generally do not require liver transplantation unless they are **very large**, symptomatic, or show signs of **malignant transformation** or rupture, which are rare indications compared to other severe liver diseases. - Management usually involves **surgical resection** or close monitoring, not transplantation. *Primary sclerosing cholangitis* - **Primary sclerosing cholangitis (PSC)** is a chronic cholestatic liver disease that often progresses to **cirrhosis** and liver failure, making it a common indication for liver transplantation. - It also carries an increased risk of **cholangiocarcinoma**, an indication for transplant if diagnosed early under specific criteria. *Fulminant hepatitis* - **Fulminant hepatitis** (acute liver failure) involves severe, rapid onset liver dysfunction with **encephalopathy** and coagulopathy in individuals without pre-existing liver disease. - It is a **life-threatening condition** that often necessitates urgent liver transplantation. *Alcoholic cirrhosis* - **Alcoholic cirrhosis** is a leading cause of end-stage liver disease and is a common indication for liver transplantation, often after a period of **abstinence** from alcohol. - Transplantation is considered when the liver damage is irreversible and life-threatening, and the patient meets specific criteria, including a commitment to sobriety.
Question 8: What is the method of delivery for islet cell transplantation in diabetes mellitus?
- A. Thigh
- B. Pelvis
- C. Forearm muscles
- D. Infused into the portal vein (Correct Answer)
Explanation: ***Infused into the portal vein*** - Islet cells are infused into the **portal vein**, which carries them to the liver, where they engraft and begin producing insulin. - The **liver** provides a rich blood supply and an immunosuppressive environment favorable for islet survival and function. *Pelvis* - While other cell therapies might be delivered to the pelvis, it is not the standard site for **islet cell transplantation**. - The pelvis lacks the specific microenvironment and blood flow dynamics optimal for islet engraftment and function. *Thigh* - The thigh is not a typical site for **islet cell transplantation** due to its less favorable vascularization and tissue environment compared to the liver. - Delivering islets to the thigh would likely result in poorer survival and integration of the transplanted cells. *Forearm muscles* - **Forearm muscles** are not the preferred location for islet cell transplantation due to inadequate blood supply and an unsuitable immunological environment. - This site would not optimize cell survival or insulin secretion.
Question 9: Which of the following is a cause of post-transplantation hypertension? I. Rejection II. Cyclosporine nephrotoxicity III. Renal transplant artery stenosis (RTAS) IV. Recurrent disease in the allograft. Select the correct option.
- A. None of the above are correct causes.
- B. I, II, and IV are correct causes.
- C. I and III are correct causes.
- D. All of the options are correct causes of post-transplantation hypertension. (Correct Answer)
Explanation: ***All of the options are correct causes of post-transplantation hypertension.*** - Post-transplantation hypertension often has a multifactorial etiology, with **rejection**, **cyclosporine nephrotoxicity**, **renal transplant artery stenosis (RTAS)**, and **recurrent disease in the allograft** all being significant contributors. - Each of these conditions can lead to mechanisms that elevate blood pressure, such as **renal ischemia**, activation of the **renin-angiotensin system**, and inflammatory responses affecting renal function. *I, II, and IV are correct causes.* - This option is incorrect because it excludes **renal transplant artery stenosis (RTAS)** (III), which is a well-established cause of secondary hypertension in transplant recipients due to reduced blood flow to the allograft. - **RTAS** activates the renin-angiotensin-aldosterone system (RAAS), leading to **vasoconstriction** and **sodium retention**, contributing to hypertension. *I and III are correct causes.* - This option is incorrect as it omits other crucial causes like **cyclosporine nephrotoxicity** (II) and **recurrent disease in the allograft** (IV), both of which are documented contributors to post-transplantation hypertension. - **Cyclosporine nephrotoxicity** causes afferent arteriolar vasoconstriction and glomerulosclerosis, directly increasing blood pressure. *None of the above are correct causes.* - This option is incorrect because **rejection**, **cyclosporine nephrotoxicity**, **renal transplant artery stenosis (RTAS)**, and **recurrent disease in the allograft** are all recognized and significant causes of post-transplantation hypertension. - Each condition has distinct pathological mechanisms that contribute to **elevated blood pressure** in transplant recipients.
Question 10: Xenograft is transplantation of tissue:
- A. From same species
- B. From genetically identical twins
- C. From a different species (Correct Answer)
- D. From one part of body to another
Explanation: ***From a different species*** - A **xenograft** (or heterograft) is the transplantation of cells, tissues, or organs from **one species to another**, such as from a pig to a human. - This type of transplant faces significant immunological challenges due to the **genetic disparity** between the donor and recipient. *From same species* - This describes an **allograft** (or homograft), where tissue is transplanted between genetically distinct individuals of the **same species**. - Examples include organ transplants between unrelated humans. *From genetically identical twins* - This describes an **isograft** (or syngeneic graft), which involves transplantation between **genetically identical individuals**, such as monozygotic twins. - These grafts typically have the **highest success rate** due to minimal immune rejection. *From one part of body to another* - This describes an **autograft**, where tissue is transplanted from one site to another **within the same individual**. - Examples include a skin graft from the thigh to a burned area on the arm or a **coronary artery bypass graft** using a leg vein; these grafts are not rejected as they originate from the patient's own body.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free